Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
Related to this article
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
Advertisement
Advertisement
Trending on AJMC
1
Gene Silencers Cut ATTR-CM Events, Mostly in Patients Off Stabilizers
2
Autoimmune Hepatitis Regimens Carry Distinct Adverse Event Signals
3
Genetic Analysis Links Insomnia Liability to Higher Inflammation Marker
4
Tirzepatide Linked to Lower Death or HF Event Rates in T2D, HF
5